細胞和基因療法市場規模、佔有率和成長分析：按治療方法、方式、適應症、最終用戶和地區分類——2026-2033年產業預測

2024 年全球細胞和基因治療市場價值為 294.4 億美元，預計到 2025 年將成長至 348.8 億美元，到 2033 年將成長至 1356.2 億美元，在預測期（2026-2033 年）內複合年成長率為 18.5%。

癌症、心血管疾病和罕見遺傳疾病等慢性病的日益普及是細胞和基因治療市場的主要驅動力。現有治療方法往往無法提供長期解決方案，因此醫療專業人員和製藥公司都在尋求能夠提供標靶、個人化治療的突破性治療方法。隨著篩檢技術的進步和人口老化導致確診患者數量增加，對先進治療方法的需求不斷成長，推動了全球範圍內的投資、臨床試驗和商業化進程。技術創新，特別是CRISPR-Cas9等基因編輯技術，對該市場至關重要，它能夠實現精準的DNA修飾，從而提高患者安全性和監管可行性。這項進展不僅縮短了研發時間和降低了成本，還提高了治療方法成功的可能性，進而推動了這個充滿活力的產業的擴張。

全球細胞和基因治療市場按治療類型、治療領域、最終用戶和地區進行細分。依治療類型分類，市場分為細胞治療和基因治療兩大類。依治療領域分類，市場分為心血管疾病、癌症、遺傳性疾病、罕見疾病、腫瘤學、血液學、眼科學、感染疾病、神經系統疾病及其他。依最終用戶分類，市場分為醫院、癌症治療中心等三大類。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球細胞和基因治療市場的成長要素

遺傳性疾病和罕見疾病的日益普遍正顯著地推動細胞和基因治療市場的發展。這些創新治療方法為治癒曾經被認為無法治癒的疾病帶來了希望。隨著越來越多的患者尋求治療方法，以及診斷工具的日益精準，專業化、高效治療方法的需求正急劇成長。這種對標靶治療的日益關注進一步加速了全球細胞和基因治療產業的擴張和發展，凸顯了應對複雜健康挑戰的創新方法的迫切需求。

全球細胞和基因治療市場的限制因素

全球細胞和基因治療市場面臨許多限制因素，其中之一便是這些治療方法的研發難度。研發需要全面的臨床前研究、複雜的臨床試驗、嚴格的監管核准。這些流程的漫長性阻礙了療法及時進入市場，並推高了研發成本。對於中小企業而言，這項挑戰尤其突出，它們往往難以應對漫長的投資週期，最終影響其推動創新和在全球推出新治療方法的能力。因此，市場在充分發揮其潛力和拓展治療選擇方面受到限制。

細胞和基因治療市場的全球趨勢

全球細胞和基因治療市場正經歷著向「個人化醫療」的變革性轉變，即根據個別基因譜量身定做治療方法。這種創新方法對罕見疾病或複雜疾病患者尤其有益，因為它不僅能提高治療效果，還能最大限度地減少副作用。對個人化解決方案的關注正在推動研發領域的顯著進步，促使製藥公司開發標靶治療，以滿足患者的多樣化需求。因此，這一趨勢正在推動市場成長，並凸顯以患者為中心的策略在不斷發展的醫療保健解決方案模式中的重要性。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 價值鏈分析
• 價格分析
• 案例研究
• 監理情勢
• 技術評估

全球細胞和基因治療市場規模：按治療方法分類

• 細胞療法
• 基因治療

全球細胞和基因治療市場規模：按治療方式分類

• 體內
• Ex Vivo

全球細胞和基因治療市場規模：按適應症分類

• 腫瘤學
• 心血管疾病
• 神經系統疾病
• 肌肉骨骼疾病
• 眼科疾病
• 代謝性疾病和遺傳性疾病
• 感染疾病
• 其他

全球細胞和基因治療市場規模：按最終用戶分類

• 醫院和診所
• 學術研究機構
• 生物製藥和生物技術公司
• 細胞治療中心

全球細胞和基因治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novartis
• Gilead Sciences
• Bristol Myers Squibb
• bluebird bio
• Kite Pharma
• Sangamo Therapeutics
• Moderna
• Editas Medicine
• Cellectis
• Orchard Therapeutics
• UniQure
• Regenxbio
• Spark Therapeutics
• Fosun Pharma
• MeiraGTx
• Aevitas Therapeutics
• Treadwell Therapeutics
• Allogene Therapeutics
• Zymeworks
• Iovance Biotherapeutics

結論與建議

Global Cell & Gene Therapy Market size was valued at USD 29.44 Billion in 2024 and is poised to grow from USD 34.88 Billion in 2025 to USD 135.62 Billion by 2033, growing at a CAGR of 18.5% during the forecast period (2026-2033).

The growing prevalence of chronic conditions, including cancer, cardiovascular diseases, and rare genetic disorders, significantly propels the cell and gene therapy market. Existing treatments often do not provide long-term solutions, leading healthcare providers and pharmaceutical companies to seek groundbreaking therapies that offer targeted, personalized approaches. As more patients are diagnosed, driven by improved screening and an aging demographic, the demand for advanced therapies intensifies, fostering increased investment, clinical trials, and commercialization globally. Technological innovations, particularly in gene editing techniques like CRISPR-Cas9, are pivotal in this market, allowing for precise DNA modifications that enhance patient safety and regulatory viability. This progress not only streamlines research and development timelines and costs but also amplifies the potential for successful therapies, driving expansion in this dynamic sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell & Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell & Gene Therapy Market Segments Analysis

The global cell and gene therapy market is segmented based on therapy type, therapeutic class, end-users, and region. In terms of therapy type, the market is bifurcated into cell therapy and gene therapy. Based on therapeutic class, the market is segmented into cardiovascular disease, cancer, genetic disorder, rare diseases, oncology, hematology, ophthalmology, infectious disease, neurological disorders, and others. Based on end-users, the market is trifurcated into hospitals, cancer care centers, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Central & South America and the Middle East & Africa.

Driver of the Global Cell & Gene Therapy Market

The increasing prevalence of genetic disorders and rare diseases significantly propels the advancement of the cell and gene therapy market. These innovative therapies present the opportunity for cures for conditions that were once considered untreatable. As more patients seek solutions and the accuracy of diagnostic tools enhances, there is a notable surge in demand for specialized, effective treatments. This growing interest in targeted therapies further drives the expansion and evolution of the global cell and gene therapy sector, highlighting the urgent need for innovative approaches in addressing complex health challenges.

Restraints in the Global Cell & Gene Therapy Market

The Global Cell & Gene Therapy market faces significant restraints due to the demanding nature of developing these therapies, which requires comprehensive preclinical research, intricate clinical trials, and strict regulatory approvals. The extended timelines associated with these processes hinder timely market entry and elevate research and development costs. This challenge is particularly pronounced for smaller companies, as they often find it difficult to navigate the prolonged investment cycles, ultimately impacting their ability to innovate and accelerate the introduction of new therapies on a global scale. As a result, the market experiences limitations in maximizing its potential and advancing treatment options.

Market Trends of the Global Cell & Gene Therapy Market

The global cell and gene therapy market is witnessing a transformative shift towards personalized medicine, which tailors treatments to individual genetic profiles. This innovative approach not only enhances the effectiveness of therapies but also minimizes adverse effects, making it particularly beneficial for patients with rare and complex conditions. The focus on personalized solutions is fostering substantial advancements in research and development, encouraging pharmaceutical companies to pioneer targeted therapies that cater to diverse patient needs. As a result, this trend is propelling market growth, emphasizing the importance of patient-centric strategies in the evolving landscape of healthcare solutions.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Cell and Gene Therapy Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Cell Therapy
• Gene Therapy

Global Cell and Gene Therapy Market Size by Modality & CAGR (2026-2033)

• Market Overview
• In Vivo
• Ex Vivo

Global Cell and Gene Therapy Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Musculoskeletal Disorders
• Ophthalmic Disorders
• Metabolic & Genetic Disorders
• Infectious Diseases
• Others

Global Cell and Gene Therapy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Academic & Research Institutes
• Biopharmaceutical & Biotechnology Companies
• Cell Therapy Centers

Global Cell and Gene Therapy Market Size & CAGR (2026-2033)

• North America (Therapy Type, Modality, Indication, End User)
  • US
  • Canada
• Europe (Therapy Type, Modality, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Modality, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Modality, Indication, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Modality, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UniQure
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regenxbio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spark Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fosun Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aevitas Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Treadwell Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations